FDA to consult experts on Avastin
From Times Wire Services
The Food and Drug Administration will ask outside experts Wednesday whether Genentech Inc.’s Avastin should be approved to treat breast cancer, despite mixed results in company studies.
After reviewing the South San Francisco firm’s data, the agency said patients on Avastin and chemotherapy had slower cancer progression but did not survive longer overall than patients on chemotherapy alone.
Shares of Genentech fell $2.75, or 3.6%, to $73.50.
